Tag Archives: Swayampakula Ramakanth

H.C. Wainwright Thinks Corvus Pharmaceuticals’ Stock is Going to Recover

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Corvus Pharmaceuticals (CRVS – Research Report), with a price target of $6.00. The company’s shares closed last Monday at $2.14, close to its 52-week low

H.C. Wainwright Thinks EKSO BIONICS’s Stock is Going to Recover

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on EKSO BIONICS (EKSO – Research Report) today and set a price target of $11.00. The company’s shares closed last Thursday at $4.95, close to its 52-week low of $3.96. According

Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (NASDAQ: CORT), Ligand Pharma (NASDAQ: LGND) and Seagen (NASDAQ: SGEN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Corcept Therapeutics (CORT – Research Report), Ligand Pharma (LGND – Research Report) and Seagen (SGEN – Research Report) with bullish sentiments. Corcept

H.C. Wainwright Keeps Their Buy Rating on AVEO Pharma (AVEO)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on AVEO Pharma (AVEO – Research Report), with a price target of $19.00. The company’s shares closed last Friday at $6.13, close to its 52-week low

Analysts Offer Insights on Services Companies: ALX Oncology Holdings (NASDAQ: ALXO) and PLBY Group (NASDAQ: PLBY)

There’s a lot to be optimistic about in the Services sector as 2 analysts just weighed in on ALX Oncology Holdings (ALXO – Research Report) and PLBY Group (PLBY – Research Report) with bullish sentiments. ALX Oncology Holdings (ALXO) H.C.

Analysts Are Bullish on Top Materials Stocks: Codexis (CDXS), Solitario Exploration & Royalty (XPL)

There’s a lot to be optimistic about in the Materials sector as 2 analysts just weighed in on Codexis (CDXS – Research Report) and Solitario Exploration & Royalty (XPL – Research Report) with bullish sentiments. Codexis (CDXS) H.C. Wainwright analyst